Who makes OCU400 Second Eye Dosing?

OCU400 Second Eye Dosing is developed by Ocugen.

What development phase is OCU400 Second Eye Dosing in?

OCU400 Second Eye Dosing is in Phase 1.

Last reviewed 2026-04-19 · How we verify

OCU400 Second Eye Dosing

Ocugen · Phase 1 active Small molecule

At a glance

Generic name	OCU400 Second Eye Dosing
Sponsor	Ocugen
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OCU400 Second Eye Dosing CI brief — competitive landscape report
OCU400 Second Eye Dosing updates RSS · CI watch RSS
Ocugen portfolio CI